Printer Friendly

Staying within the boundaries.

The debate about conflicts of interest is extremely important and timely ("Should experts with potential conflicts of interest be allowed to serve on FDA advisory panels?" Pro & Con, September 2005, p. 16).

As psychiatrists, it behooves us to view this as a boundary issue, as we do with patients. Although it is a fact of life that physicians will be paid for rendering services to drug companies, we should handle it the same way we do with sex and our patients: We don't belong in bed with them.

My last remuneration for a drug study was more than 45 years ago, when I tested a combination of dioxolane and reserpine. When I reported that the side effects were greater than the salutary effects, I heard no more from the company! Incidentally, a professor at another university published a positive report. The product was never marketed.

Sheldon B. Cohen, M.D.

Atlanta
COPYRIGHT 2006 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTERS
Author:Cohen, Sheldon B.
Publication:Clinical Psychiatry News
Article Type:Letter to the editor
Date:Jan 1, 2006
Words:151
Previous Article:Enough already.
Next Article:Combo therapy appears effective in treating ADHD.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters